136. Ritter, J.L. Fenofibrate-induced elevation in serum creatinine / J.L. Ritter, S.
Nabulsi // Pharmacotherapy. - 2001. - Vol. 21. - P.l 145-1149.
137. Robins, S.J. Response of serum triglycerides of endogenous origin to the
administration of triglyceride-rich lipid particles / S.J. Robins // Am J Physiol. -
1989. - Vol. 257. - P.860-865.
138. Roche, H.M. The impact of postprandial lipemia in accelerating
atherothrombosis / H.M. Roche, M.J. Gibney // J Cardiovasc Risk. - 2000. - Vol.
7 . - P . 3 17-324.
139. Rubins, H.B. Distribution of lipids in 8,500 men with coronary artery disease /
H.B. Rubins, S.J. Robins, D. Collins, et al. // Am J Cardiol. - 1995. - Vol. 75. -
P.l 196-1201.
140. Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World
Health Organization, 2003.
141. Schedlbauer, A. How can adherence to lipid-lowering medication be improved?
A systematic review of randomized controlled trials / A. Schedlbauer, K.
Schroeder, T.Fahey // Farm Pract. - 2007. - Vol. 24. - P.380-387.
142. Sacks, F.M. The role of high-density lipoprotein cholesterol in the prevention and
treatment of coronary heart disease: expert group recommendations / F.M. Sacks
// Am J Cardiol. - 2002. - Vol. 90. - P. 139-143.
143. Schaefer, E.J. Factors associated with low and elevated plasma HDL-cholesterol
and apoA-I levels in the Framingham Offspring Study / E.J. Schaefer // J Lipid
Res. - 1994. - Vol. 35. - P.871-882.
144. Shah, P.K. Circulating markers of inflammation for vascular risk prediction: are
they ready for prime time / P.K. Shah // Circulation. - 2000. - Vol. 101. -
P .1758-1759.
145. Shaper, A.G. Risk factors for ischemic heart disease: The prospective phase of
the British Regional Heart Study / A.G. Shaper // J. Epidemiology and
Community Health. - 1985. — Vol. 39. — P. 197—209.
146. Shepherd, J. for the West of Scotland Coronary Prevention Study Group.
Prevention of coronary heart disease with pravastatin in men with
98
